Effectiveness and tolerability of programmed cell death protein-1 inhibitor + chemotherapy compared to chemotherapy for upper gastrointestinal tract cancers

Figure 4 Subgroup analysis of overall survival and progression-free survival based on programmed death-ligand 1 combined positive score and ≥ 3 grades adverse events. A: Subgroup analysis of overall survival based on programmed death-ligand 1 (PD-L1) combined positive score (CPS); B: Subgroup analysis of progression-free survival based on PD-L1 CPS score; C: Subgroup analysis of ≥ 3 grades adverse events. HR: Hazard ratio; OR: Odds ratio; CI: Confidence interval.